# Simulations Plus, Inc. (SLP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $15.94 (-0.44%)

> Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and related industries. The company develops advanced tools such as GastroPlus for physiologically based pharmacokinetic modeling and simulation of drug absorption, DDDPlus for in vitro dissolution testing, MembranePlus for biopharmaceutical experiments, ADMET Predictor for molecular property prediction and AI-driven drug design, MonolixSuite for pharmacometrics analysis, DILIsym for quantitative systems toxicology, Thales for quantitative systems pharmacology, and Pro-ficiency for performance management in training. These solutions support drug discovery, development, preclinical and clinical trial data analysis, regulatory submissions, and areas like ADMET prediction, safety assessment, and treatment regimen optimization. Simulations Plus also offers expert consulting in pharmacometrics, PBPK modeling, and regulatory interactions, serving major pharmaceutical, biotech, agrochemical, chemical, and consumer goods companies worldwide. Founded in 1996 and headquartered in Lancaster, California, the company plays a key role in accelerating model-informed drug development and enhancing R&D efficiency across the biopharma sector.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/SLP)